5 unknown. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 5 |
| Phase 1 | 2 | Unknown 2 |
Follow Turcot syndrome: new trials by email Literature Review of Turcot syndrome trials Research Report on Turcot syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody - Colorectal Cancer, Mismatch Repair-deficient (dMMR) | Phase 2 | Unknown | LiuYing | 22 | 2023-06-20 | 2023-06-22 |
| Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer Neoadjuvant therapy with PD-L1 inhibitor - Colorectal Cancer, Mismatch Repair-deficient (dMMR) | Phase 2 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 26 | 2022-05-05 | 2022-05-12 |
| Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer Sintilimab, Hypofractionated Radiotherapy - Anti-PD-1 Antibody, Radiotherapy | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2020-08-14 | 2024-08-06 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer Avelumab - Metastatic Colorectal Cancer | Phase 2 | Unknown | Asan Medical Center | 33 | 2017-05-22 | 2020-04-03 |
Colorectal Neoplasms (3) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Rectal Neoplasms (1) · Sarcoma (1) · Stomach Neoplasms (1) · Tertiary Lymphoid Structures (1) · Thyroid Neoplasms (1)
Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Rectal Diseases (4) · Colonic Diseases (3) · Adenocarcinoma (1) · Adenoma (1) · Biliary Tract Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1)
Neoadjuvant Therapy (2) · Clinical Trials, Phase II as Topic (1) · Immune Checkpoint Inhibitors (1) · Radiation Dose Hypofractionation (1) · avelumab (1) · regorafenib (1) · sintilimab (1)
Asan Medical Center (1) · Institut Bergonié (1) · LiuYing (1) · Third Affiliated Hospital, Sun Yat-Sen University (1) · West China Hospital (1)
China (3) · France (1) · South Korea (1)
Meng Qiu, M.D. (1) · Tae Won Kim, Professor (1) · Ying Liu, MD (1)
PMID 34965951, PMID 34998048, PMID 35352512, PMID 40204996, PMID 40579407
2016 (1)